To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
AstraZeneca
NeoImmuneTech
AstraZeneca
Hoffmann-La Roche
I-Mab Biopharma US Limited
Seagen Inc.
Pfizer
Hoffmann-La Roche
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Gilead Sciences
Zenith Epigenetics
CytoDyn, Inc.
Incyte Corporation
GlaxoSmithKline
Formation Biologics
Numab Therapeutics AG
BeiGene
G1 Therapeutics, Inc.
Merck Sharp & Dohme LLC
Sellas Life Sciences Group
Novartis
Hutchmed
ImmunityBio, Inc.
HiberCell, Inc.
ADC Therapeutics S.A.
Amgen
Eli Lilly and Company
Hoffmann-La Roche
Ayala Pharmaceuticals, Inc,
AstraZeneca
Hoffmann-La Roche
Genmab
Genmab
AstraZeneca
EMD Serono
Nektar Therapeutics
Nektar Therapeutics
Calithera Biosciences, Inc
Novartis
Corcept Therapeutics
Tesaro, Inc.
Calithera Biosciences, Inc
Incyte Corporation
Pfizer
Novartis
Hoffmann-La Roche
Eisai Inc.
G1 Therapeutics, Inc.
Calithera Biosciences, Inc
Incyte Corporation